{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:42:04Z","timestamp":1794357724537,"version":"4.9.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Taighde Eireann - Research Ireland","doi-asserted-by":"publisher","award":["15\/SIRG\/3842"],"award-info":[{"award-number":["15\/SIRG\/3842"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Taighde Eireann - Research Ireland","doi-asserted-by":"publisher","award":["19\/FFP\/6428"],"award-info":[{"award-number":["19\/FFP\/6428"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008167","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","award":["SFI 16\/RI\/3701"],"award-info":[{"award-number":["SFI 16\/RI\/3701"]}],"id":[{"id":"10.13039\/501100008167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011704","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119273","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:56:39Z","timestamp":1775123799000},"page":"119273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer"],"prefix":"10.1016","volume":"198","author":[{"given":"Sara","family":"Noorani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00edan","family":"\u00d3 Mad\u00e1in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-1597","authenticated-orcid":false,"given":"Jojanneke","family":"Stoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lepeltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-0499","authenticated-orcid":false,"given":"Esen","family":"Efeoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Meleady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia E.","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2178-3564","authenticated-orcid":false,"given":"Naomi","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2026.119273_bib1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.clinthera.2017.08.015","article-title":"Current standards of chemotherapy for pancreatic cancer","volume":"39","author":"Saung","year":"2017","journal-title":"Clin. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2026.119273_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119273_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/cancers16050910","article-title":"Neoadjuvant and adjuvant chemotherapy for pancreatic adenocarcinoma: literature review and our experience of NAC-GS","volume":"16","author":"Aoki","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119273_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/tgh.2019.04.04","article-title":"Adjuvant treatment for pancreatic cancer","volume":"4","author":"Klaiber","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119273_bib5","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119273_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119273_bib7","article-title":"MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119273_bib8","article-title":"5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition","volume":"137","author":"Sethy","year":"2021","journal-title":"Biomed. Pharm. Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119273_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.50.4.549","article-title":"Photodynamic therapy for cancer of the pancreas","volume":"50","author":"Bown","year":"2002","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jcm9010192","article-title":"An Efficient photodynamic therapy treatment for human pancreatic adenocarcinoma","volume":"9","author":"Quilbe","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2026.119273_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.691697","article-title":"Photodynamic therapy-current limitations and novel approaches","volume":"9","author":"Gunaydin","year":"2021","journal-title":"Front. Chem."},{"issue":"32","key":"10.1016\/j.biopha.2026.119273_bib12","doi-asserted-by":"crossref","first-page":"13089","DOI":"10.1021\/acs.inorgchem.3c01982","article-title":"Phototoxicity of tridentate Ru(II) polypyridyl complex with expanded bite angles toward mammalian cells and multicellular tumor spheroids","volume":"62","author":"Curley","year":"2023","journal-title":"Inorg. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119273_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cptc.202000283","article-title":"It takes three to Tango - the length of the oligothiophene determines the nature of the long-lived excited state and the resulting photocytotoxicity of a Ru(II) photodrug","volume":"5","author":"Chettri","year":"2021","journal-title":"ChemPhotoChem"},{"issue":"43","key":"10.1016\/j.biopha.2026.119273_bib14","doi-asserted-by":"crossref","first-page":"23397","DOI":"10.1021\/jacs.3c01135","article-title":"Ruthenium-based photoactivated chemotherapy","volume":"145","author":"Bonnet","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2026.119273_bib15","series-title":"Springer Handbook of Inorganic Photochemistry [Internet]","first-page":"1073","article-title":"Luminescent Metal Complexes in Bioimaging","author":"Byrne","year":"2022"},{"issue":"10","key":"10.1016\/j.biopha.2026.119273_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119273_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat. Rev. Methods Prim."},{"issue":"17","key":"10.1016\/j.biopha.2026.119273_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1039\/C39950001799","article-title":"Stepwise syntheses of mono- and di-nuclear ruthenium tpphz complexes [(bpy)2Ru(tpphz)]2\u2013 and [(bpy)2Ru(tpphz)Ru(bpy)2]4+{tpphz = tetrapyrido[3,2-a: 2\u2032,3\u2032-c: 3\u2033,2\u2033-h: 2\u2033,3\u2034-j]phenazine}","author":"Bolger","year":"1995","journal-title":"J. Chem. Soc. Chem. Commun."},{"issue":"47","key":"10.1016\/j.biopha.2026.119273_bib19","doi-asserted-by":"crossref","first-page":"40869","DOI":"10.1039\/C6RA06086B","article-title":"An efficient route to asymmetrically diconjugated tris(heteroleptic) complexes of Ru(II)","volume":"6","author":"Burke","year":"2016","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.biopha.2026.119273_bib20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1021\/jacs.8b09999","article-title":"Exploring the cytotoxicity, uptake, cellular response, and proteomics of mono- and dinuclear DNA light-switch complexes","volume":"141","author":"Jarman","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.biopha.2026.119273_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"39","key":"10.1016\/j.biopha.2026.119273_bib22","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.3748\/wjg.v27.i39.6527","article-title":"Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities","volume":"27","author":"Jain","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119273_bib23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","article-title":"The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview","volume":"16","author":"Qui\u00f1onero","year":"2019","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119273_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000065068","article-title":"Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes","volume":"62","author":"Shi","year":"2002","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","article-title":"Organoid technology and applications in cancer research","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119273_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcmgh.2017.12.004","article-title":"Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer","volume":"5","author":"Moreira","year":"2018","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib27","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41598-020-59368-7","article-title":"Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development","volume":"10","author":"Nelson","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119273_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/organoids1020013","article-title":"Pancreatic cancer 3D cell line organoids (CLOs) maintain the phenotypic characteristics of organoids and accurately reflect the cellular architecture and heterogeneity in vivo","volume":"1","author":"Noorani","year":"2022","journal-title":"Organoids"},{"issue":"23","key":"10.1016\/j.biopha.2026.119273_bib29","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-21-1681","article-title":"Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma","volume":"27","author":"Farshadi","year":"2021","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119273_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119273_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","article-title":"Drug resistance in pancreatic cancer: impact of altered energy metabolism","volume":"114","author":"Grasso","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119273_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115902","article-title":"The relationship between tumor metabolism and 5-fluorouracil resistance","volume":"218","author":"Hu","year":"2023","journal-title":"Biochem. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119273_bib34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.119273_bib35","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjc.6605007","article-title":"De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy","volume":"100","author":"Mashima","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119273_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3904947","article-title":"FASN protein overexpression indicates poor biochemical recurrence-free survival in prostate cancer","volume":"2020","author":"Cao","year":"2020","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib37","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i1.98409","article-title":"Dysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma","volume":"17","author":"Poenaru","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119273_bib38","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1210\/en.2006-0486","article-title":"Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?","volume":"147","author":"Lupu","year":"2006","journal-title":"Endocrinology"},{"issue":"17","key":"10.1016\/j.biopha.2026.119273_bib39","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1073\/pnas.1617709114","article-title":"Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma","volume":"114","author":"Gouw","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib40","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1038\/s41467-022-31963-4","article-title":"Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer","volume":"13","author":"Bartolacci","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib41","first-page":"89","article-title":"Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers","volume":"2","author":"Yang","year":"2011","journal-title":"Int. J. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119273_bib42","first-page":"2211","article-title":"Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer","volume":"15","author":"Tian","year":"2018","journal-title":"Oncol. Lett."},{"issue":"20","key":"10.1016\/j.biopha.2026.119273_bib43","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","article-title":"De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer","volume":"77","author":"Tadros","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119273_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101143","article-title":"Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer","volume":"62","author":"Steen","year":"2025","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12967-024-04931-3","article-title":"PITPNC1 suppress CD8+ T cell immune function and promote radioresistance in rectal cancer by modulating FASN\/CD155","volume":"22","author":"Liang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119273_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148550","article-title":"Clinical development of metabolic inhibitors for oncology","volume":"132","author":"Lemberg","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"issue":"5","key":"10.1016\/j.biopha.2026.119273_bib49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119273_bib50","first-page":"265","article-title":"Rationally designed ruthenium complexes for breast cancer therapy","volume":"25","author":"Golbaghi","year":"2020","journal-title":"Mol. Basel Switz."},{"issue":"27","key":"10.1016\/j.biopha.2026.119273_bib51","doi-asserted-by":"crossref","first-page":"14963","DOI":"10.1021\/jacs.3c04855","article-title":"Cyclic ruthenium-peptide conjugates as integrin-targeting phototherapeutic prodrugs for the treatment of brain tumors","volume":"145","author":"Zhang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"24","key":"10.1016\/j.biopha.2026.119273_bib52","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.3390\/cancers15245753","article-title":"Establishment and thorough characterization of xenograft (PDX) models derived from patients with pancreatic cancer for molecular analyses and chemosensitivity testing","volume":"15","author":"Behrens","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119273_bib53","doi-asserted-by":"crossref","DOI":"10.1039\/D5CC05629B","article-title":"Targeted photodynamic therapy for pancreatic cancer: recent innovations from fundamentals to in vivo and clinical applications (2020\u20132025)","author":"Sarr","year":"2026","journal-title":"Chem. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2026.119273_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s41061-022-00384-8","article-title":"Metal peptide conjugates in cell and tissue imaging and biosensing","volume":"380","author":"Gkika","year":"2022","journal-title":"Top. Curr. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119273_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13046-023-02931-7","article-title":"Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy","volume":"43","author":"Alcal\u00e1","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.biopha.2026.119273_bib56","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.7150\/thno.34015","article-title":"Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage","volume":"9","author":"Zhou","year":"2019","journal-title":"Theranostics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:58:53Z","timestamp":1779245933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"alternative-id":["S0753332226003069"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119273","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119273"}}